Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GRI Bio ( (GRI) ) has shared an update.
On December 11, 2025, GRI Bio, Inc. initiated a public offering involving shares of common stock, pre-funded warrants, and Series F warrants, aiming to raise approximately $6.7 million. The company plans to use the proceeds for working capital, product development, and general corporate purposes, with expectations to fund operations into the fourth quarter of 2026. The offering, expected to close on December 12, 2025, includes agreements with institutional investors and restrictions on further stock issuance for a specified period.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
Average Trading Volume: 554,632
Technical Sentiment Signal: Sell
Current Market Cap: $3.96M
For a thorough assessment of GRI stock, go to TipRanks’ Stock Analysis page.